10 March 2020
The Global Fund, Stop TB Partnership Global Drug Facility and Unitaid are inviting manufacturers of antiretroviral (HIV/AIDS), antihepatitis B and C, antituberculosis and antimalarial medicines to submit an expression of interest to have their products evaluated by the Expert Review Panel for Pharmaceutical Products.
Detailed information about the review process and submission requirements for this Round 22 opportunity can be found in the document below.
Once all expressions of interest have been received, the Expert Review Panel will be responsible for reviewing and judging their eligibility and whether to perform a risk-benefit assessment of the products submitted.
The deadline for submission of an expression of interest is Friday, 1 May 2020 (COB). Mid May 2020, the Global Fund Secretariat will communicate to manufacturers the outcomes of the review of the completeness of the documents submitted. The results of the product evaluations are expected to be released end of July 2020.